---
layout: default
title: Deferasirox
parent: Moderate Evidence (L3-L4)
nav_order: 253
evidence_level: L4
indication_count: 5
---

# Deferasirox
{: .fs-9 }

Evidence Level: **L4** | Predicted Indications: **5** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Deferasirox: From Chronic Iron Overload to HIV Infectious Disease

## One-Sentence Summary

Deferasirox is an iron chelator, and the Evidence Pack indicates it is used in iron-overload settings such as thalassemia major.
The TxGNN model predicts it may be effective for **HIV infectious disease**, but there are **0 clinical trials** and only **2 publications** (1 preclinical study and 1 drug-approval summary), so this is a research question rather than an actionable candidate.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Chronic iron overload (inferred from its role as an iron chelator; the Canadian licence records contain no indication text) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L4 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 20 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Deferasirox is an iron chelator, and its efficacy in iron overload has been established. Mechanistically, iron status may influence HIV biology, so the drug may be applicable to HIV infection.

The main support is one preclinical study (PMID 34550543). It shows that iron inside endolysosomes restricts HIV-1 Tat-mediated LTR transactivation, by increasing Tat oligomerization and β-catenin expression. This suggests a plausible link between iron homeostasis and HIV transcription.

There are important limits:
- The abstract does not show that deferasirox itself was tested.
- The direction of effect is unresolved. Chelating iron could help or hurt, because in this study higher endolysosomal iron restricted Tat activity.
- There are no clinical trials and no human efficacy data.

**Other predictions:**
- **Chronic hepatitis C infection (rank 2, score 99.39%, L4):** Iron overload and HCV-related liver injury are linked in thalassemia major. Deferasirox may act as an adjunct that limits iron-driven liver damage, but there is no evidence of a direct antiviral effect.
- **Ranks 3–5 (L5):** A neurodevelopmental disorder, an obsolete familial combined hyperlipidemia term, and dermatofibrosarcoma protuberans are supported only by knowledge-graph scores. They have no trials, no literature and no identified mechanism. The hyperlipidemia term is obsolete in the ontology, so that prediction may be a mapping artifact.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [34550543](https://pubmed.ncbi.nlm.nih.gov/34550543/) | 2021 | Preclinical mechanistic study | Journal of Neurovirology | Endolysosomal iron restricts HIV-1 Tat-mediated LTR transactivation by increasing Tat oligomerization and β-catenin expression. Deferasirox is not confirmed as the tested agent. |
| [16529348](https://pubmed.ncbi.nlm.nih.gov/16529348/) | 2006 | Review (new drug approval summary) | Journal of the American Pharmacists Association | Summary of newly approved drugs including deferasirox. It contains no HIV-specific efficacy data. |

---

## Canada Market Information

Showing 5 of 20 authorizations. Dosage form and approved-indication text are not recorded in the licence data.

| DIN | Product Name |
|---------|------|
| 2485281 | APO-DEFERASIROX (TYPE J) |
| 2461560 | APO-DEFERASIROX |
| 2464470 | SANDOZ DEFERASIROX |
| 2507331 | TARO-DEFERASIROX (TYPE J) |
| 2452227 | JADENU |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV prediction has a high model score (99.40%) but rests on one preclinical study that does not clearly test deferasirox, and the direction of effect is unresolved. With no clinical trials, no human data and no safety data in hand, the finding stays at the research-question stage (L4, S0).

**To proceed, the following is needed:**
- Health Canada package insert warnings and contraindications, which are required before any safety screening.
- Mechanism of action data, for example from DrugBank.
- Direct in vitro testing of deferasirox on HIV replication and Tat transactivation, to establish the direction of effect.
- Confirmation of the original approved indication from the Canadian product monographs, since the licence records have no indication text.
- For the hepatitis C prediction, evaluation of deferasirox as an adjunct for iron-driven liver injury in thalassemia populations.

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

